158 related articles for article (PubMed ID: 9166393)
1. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
[TBL] [Abstract][Full Text] [Related]
2. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Moghetti P; Castello R; Zamberlan N; Rossini M; Gatti D; Negri C; Tosi F; Muggeo M; Adami S
J Clin Endocrinol Metab; 1999 Apr; 84(4):1250-4. PubMed ID: 10199763
[TBL] [Abstract][Full Text] [Related]
4. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
6. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
7. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Diamond T; McGuigan L; Barbagallo S; Bryant C
Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
[TBL] [Abstract][Full Text] [Related]
8. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
9. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
10. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
11. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
12. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
14. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
Anderson FH; Francis RM; Bishop JC; Rawlings DJ
Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
16. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
17. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
Masud T; Mulcahy B; Thompson AV; Donnelly S; Keen RW; Doyle DV; Spector TD
Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
[TBL] [Abstract][Full Text] [Related]
18. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
Montessori ML; Scheele WH; Netelenbos JC; Kerkhoff JF; Bakker K
Osteoporos Int; 1997; 7(1):52-8. PubMed ID: 9102064
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
Roux C; Oriente P; Laan R; Hughes RA; Ittner J; Goemaere S; Di Munno O; Pouillès JM; Horlait S; Cortet B
J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Bolanca S; Korsić M; Dekanić D; Cvijetić S
Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
